A new technology developed at MIT enables scientists to label proteins across millions of individual cells in fully intact 3D tissues with unprecedented speed, uniformity, and versatility. Using the technology, the team was able to richly label whole rodent brains and other large tissue samples in a single day. In their new study in Nature Biotechnology, they also demonstrate that the ability to label proteins with antibodies at the single-cell level across whole brains can reveal insights left hidden by other widely used labeling methods.
Profiling the proteins that cells are making is a staple of studies in biology, neuroscience and related fields because the proteins a cell is expressing at a given moment can reflect the functions the cell is trying to perform or its response to its circumstances, such as disease or treatment. As much as microscopy and labeling technologies have advanced, enabling innumerable discoveries, scientists have still lacked a reliable and practical way of tracking protein expression at the level of millions of densely packed individual cells in whole, 3D intact tissues such as an entire mouse brain or a full region of a human brain. Often confined to thin tissue sections under slides, scientists therefore haven’t had tools to thoroughly appreciate cellular protein expression in the whole, connected systems in which it occurs.
“Conventionally, investigating the molecules within cells requires dissociating tissue into single cells or slicing it into thin sections, as light and chemicals required for analysis cannot penetrate deep into tissues. Our lab developed technologies such as CLARITY and SHIELD, which enable investigation of whole organs by rendering them transparent, but we now needed a way to chemically label whole organs to gain useful scientific insights” said study senior author Kwanghun Chung, associate professor in The Picower Institute for Learning and Memory, the Departments of Chemical Engineering and Brain and Cognitive Sciences, and the Institute for Medical Engineering and Science at MIT. “Imagine marinating a thick steak by simply dipping it in sauce. The outer layers absorb the marinade quickly and intensely, while the inner layers remain largely untouched unless the meat is soaked for an extended period. The same principle applies to chemical processing of tissues: if cells within a tissue are not uniformly processed, they cannot be quantitatively compared. The challenge is even greater for protein labeling, as the chemicals we use for labeling are hundreds of times larger than those in marinades. As a result, it can take weeks for these molecules to diffuse into intact organs, making uniform chemical processing of organ-scale tissues virtually impossible and extremely slow.”
The new approach, called “CuRVE,” represents a major advance — years in the making — toward that goal by demonstrating a fundamentally new approach to uniformly processing large and dense tissues whole. In the study, the researchers explain how they overcame the technical barriers via an implementation of CuRVE called “eFLASH,” and provide copious vivid demonstrations of the technology, including how it yielded new neuroscience insights.
“This is a significant leap, especially in terms of the actual performance of the technology,” said co-lead author Dae Hee Yun, a former MIT graduate student and now a senior application engineer at LifeCanvas Technologies, a startup company Chung founded to disseminate the tools his lab invents. The paper’s other lead author is Young-Gyun Park, a former MIT postdoctoral researcher now an assistant professor at KAIST in South Korea.
Clever chemistry
The fundamental reason why large, 3D tissue samples are hard to label uniformly is that antibodies seep into tissue very slowly, but are quick to bind to their target proteins. The practical effect of this speed mismatch is that simply soaking a brain in a bath of antibodies will mean that proteins are intensely well labeled on the outer edge of the tissue, but virtually none of the antibodies will find cells and proteins deeper inside.
To improve labeling, the team conceived of a way — the conceptual essence of CuRVE — to resolve the speed mismatch. The strategy was to continuously control the pace of antibody binding while at the same time speeding up antibody permeation throughout the tissue. To figure out how this could work and to optimize the approach, they built and ran a sophisticated computational simulation that enabled them to test different settings and parameters, including different binding rates and tissue densities and compositions.
Then they set out to implement their approach in real tissues. Their starting point was a previous technology, called “SWITCH,” in which Chung’s lab devised a way of temporarily turning off antibody binding, letting the antibodies permeate the tissue, and then turning binding back on. As well as it worked, Yun said, the team realized there could be substantial improvements if antibody binding speed could be controlled constantly, but the chemicals used in SWITCH were too harsh for such ongoing treatment. So the team screened a library of similar chemicals to find one that could more subtly and continuously throttle antibody binding speed. They found that deoxycholic acid was an ideal candidate. Using that chemical, the team could not only modulate antibody binding by varying the chemical’s concentration, but also by varying the labeling bath’s PH (or acidity).
Meanwhile, to speed up antibody movement through tissues, the team used another prior technology invented in the Chung Lab: stochastic electrotransport. That technology accelerates the dispersion of antibodies through tissue by applying electric fields.
Implementing this eFLASH system of accelerated dispersion with continuously modifiable binding speed produced the wide variety of labeling successes demonstrated in the paper. In all, the team reported using more than 60 different antibodies to label proteins in cells across whole brains of mice and rats; whole mouse embryos; other whole mouse organs including lung and heart; and blocks of brain tissue from larger animals including humans.
Notably, each of these specimens were labeled within a day, an “ultra-fast” speed for whole, intact organs, the authors said. Moreover, different preparations did not require new optimization steps.
Valuable visualizations
Among the ways the team put eFLASH to the test was by comparing their labeling to another often-used method: genetically engineering cells to fluoresce when the gene for a protein of interest is being transcribed. The genetic method doesn’t require dispersing antibodies throughout tissue, but it can be prone to discrepancies because reporting gene transcription and actual protein production are not exactly the same thing. Yun added that while antibody labeling reliably and immediately reports on the presence of a target protein, the genetic method can be much less immediate and persistent, still fluorescing even when the actual protein is no longer present.
In the study the team employed both kinds of labeling simultaneously in samples. Visualizing the labels that way, they saw many examples in which antibody labeling and genetic labeling differed widely. In some areas of mouse brains, they found that two-thirds of the neurons expressing PV (a protein prominent in certain inhibitory neurons) according to antibody labeling, did not show any genetically-based fluorescence. In another example, only a tiny fraction of cells that reported expression via the genetic method of a protein called ChAT also reported it via antibody labeling. In other words, there were cases where genetic labeling both severely underreported or overreported protein expression compared to antibody labeling.
The researchers don’t mean to impugn the clear value of using the genetic reporting methods, but instead suggest that also using organ-wide antibody labeling, as eFLASH allows, can help put that data in a richer, more complete context. For instance, given that they saw cases of significant over-reporting of PV expression in mice (and significant variation among individual mice), researchers who use whole-brain antibody labeling of PV could gain a deeper basis for analyzing genetically indicated changes in the protein.
“Our discovery of large regionalized loss of PV-immunoreactive neurons in healthy adult mice and with high individual variability emphasizes the importance of holistic and unbiased phenotyping,” the authors wrote.
Or as Yun put it, the two different kinds of labeling are, “two different tools for the job.”
In addition to Yun, Park and Chung, the paper’s other authors are Jae Hun Cho, Lee Kamentsky, Nicholas Evans, Nicholas DiNapoli, Katherine Xie, Seo Woo Choi, Alexandre Albanese, Yuxuan Tian, Chang Ho Sohn, Qiangge Zhang, Minyoung Kim, Justin Swaney, Webster Guan, Juhyuk Park, Gabi Drummond, Heejin Choi, Luzdary Ruelas, and Guoping Feng.
Funding for the study came from the Burroughs Wellcome Fund, the Searle Scholars Program, a Packard Award in Science and Engineering, a NARSAD Young Investigator Award, the McKnight Foundation, the Freedom Together Foundation, The Picower Institute for Learning and Memory, the NCSOFT Cultural Foundation and the National Institutes of Health.
